GLP-1 Adherence Gap: 60% Seniors Discontinue Semaglutide

Founders and care teams: patient drop-off in GLP‑1 programs often clusters around predictable moments — first prescription fill, initial side‑effect days, dose adjustments, and gaps between visits. Mapping those triggers allows operational teams to automate timely, non‑clinical touchpoints that address barriers before they become churn. Stay Steady uses short, behavior‑informed SMS to fill these gaps: medication reminders at fill,-side‑effect coaching in the first week, dose‑change check‑ins, and re‑engagement prompts prior to missed appointments. The result is measurable operational impact — fewer manual outreach hours, improved retention metrics, and steadier adherence without adding clinical burden. This approach is designed for scale and compliance: simple scripts, clear escalation paths, and analytics that show where patients disengage so teams can optimize workflows. For teams building sustainable GLP‑1 programs, pragmatic, timed SMS is a low‑lift lever to reduce churn and preserve clinical capacity. Learn more about the model and outcomes: https://wix.to/eEsC597 #Telehealth #PatientRetention #GLP1Care

I Had the opportunity to lead a Lunch & Learn session with a great clinical team, where I presented on Listerine products and the science and research supporting their efficacy in improving oral health outcomes. We discussed the evidence behind essential oil based mouthrinses, their role in reducing plaque and gingivitis, and how integrating evidence based adjuncts into daily care can elevate patient outcomes. It was a highly engaging session with thoughtful questions and meaningful dialogue around clinical application. What stood out most to me is how closely this aligns with principles of healthcare compliance. Ensuring that the products we recommend are supported by credible research, FDA/ADA guidance, and transparent claims is critical, not just for patient trust, but for maintaining ethical and regulatory standards in practice. Evidence based decision making is a key component of both quality care and compliance. Grateful for the opportunity to educate, collaborate, and continue bridging the gap between clinical excellence and compliance. #DentalHygiene #OralHealth #EvidenceBasedPractice #HealthcareCompliance #RiskManagement #ClinicalEducation

As adoption of oral GLP-1 therapies grows, understanding that outcomes hinge not just on medication but on what happens between doses is critical. That’s where Dario’s precision behavioral tools shine. Our solution includes a medication cabinet to support adherence tracking and reduce dose-timing drift, a grocery scanner to translate weight-loss intent into smarter real-world food decisions, and access to a personal human coach to reinforce habit formation and persistence. Together, these features create a tightly constructed intervention model – aligning pharmacotherapy with real-time awareness to reinforce sustained behavior change. For health plans and employers navigating the evolving landscape of GLP-1 therapies, a behavior-centric strategy is no longer optional – it’s essential. Read more: https://lnkd.in/eMdcBNqM #DigitalHealth #EmployerHealth #BehavioralScience #GLP1 #PopulationHealth

The prescription is not the cure…it’s the plan. Here’s the trap: ==> patients often fall in love with the pill, believing it’s a magic bullet. They skip doses, mix medications with energy drinks, or stop treatment the moment they “feel better.” Most medication errors don’t come from lack of access…they come from ⛔️late decisions, ⛔️unnecessary self-medication, ⛔️and trying to treat something that was never there. Great pharmacists understand a simple truth: ✅ medicine works best when paired with discipline and communication. ✅Quick reads of instructions, timely refills, and smart lifestyle choices break health problems down far more effectively than chasing miracle cures. Now here’s the mindset shift: ==> Pharmacy isn’t just about handing out pills…it’s about building trust. When patients embrace open communication, timely decisions, and shared responsibility for their health, treatment flows like a well-run offense. Timely passes become timely doses. Smart spacing becomes balanced routines. And challenges break down not through individual effort, but through collective wisdom. Stop dribbling pills like they’re Skittles. Trust your pharmacist..they’re the real point guard of your health.

Most employers covering GLP-1s have no idea if they're working. They see the pharmacy claims. They don't see the return. Obesity is now recognized as a disease, which means employers feel the pressure to treat it. But paying for treatment without measuring it isn't a strategy. It's a blank check. The questions that actually matter: + Are the right members getting these medications? + Is the program driving the clinical outcomes we planned for? + And is any of this showing up in medical claims? Right now, for most plans, the answer is: we don't know. That needs to change. GLP-1s are among the most expensive interventions in benefits today — and also among the least measured. The data exists. We're just not using it.

GLP-1s are everywhere. But as we've seen, not all programs are created equal. HIT Consultant Media highlighted the key comparative study data points in the most recent WW GLP-1 Results Report. In case you missed it... In a real-world comparative analysis: 🏆 WW members achieved 72% greater average weight loss than a cohort receiving compounded GLP-1s through direct-to-consumer competitor (Hims & Hers) 🏆 WW members achieved 30%+ greater average weight loss than select other competitors 🏆 Members who combined medication with WW's GLP-1 Success Program saw 61.3% greater weight loss in month one vs. medication-only approaches A prescription is a starting point. A clinically-backed, behaviorally-integrated program is what separates real, lasting results from short-term fixes. 📄 See the full HIT Consultant Media article here: https://lnkd.in/gcVbS_bE #WeightWatchers #GLP1 #WeightHealth #DigitalHealth #CompetitiveAdvantage

In a real-world comparative analysis: 🏆 WW members achieved 72% greater average weight loss than a cohort receiving compounded GLP-1s through direct-to-consumer competitor (Hims & Hers) 🏆 WW members achieved 30%+ greater average weight loss than select other competitors 🏆 Members who combined medication with WW's GLP-1 Success Program saw 61.3% greater weight loss in month one vs. medication-only approaches

"Measuring #quality indicators offers an important opportunity for #pharmacy as a profession to take medication reviews from a passive baseline assessment (just being done) to active #patient care (being done well), i.e., the next level." Read more in this editorial: https://lnkd.in/e-UF-Dpk Shania Liu Mina Tadrous Ross Tsuyuki

An important editorial for the pharmacy profession—nationally and internationally. I couldn’t agree more: in this era, it is not enough to simply demonstrate service provision; measuring the quality of care delivered is the critical step in truly demonstrating our value.

ePrescribing looks simple on the surface, but it relies on structured data moving across systems owned and managed by different organizations. Understanding how those systems connect provides a clearer view of how prescription data moves and how medication history becomes visible across care settings. https://lnkd.in/gp2bSfNG